

Antisense epidermal growth factor receptor (EGFR) transfection down-regulates EGFR expression and suppresses the malignant phenotype of human nasopharyngeal carcinoma CNE-2 cell line

DENG Fan¹, WANG Yu², ZENG Fang-yin¹, ZOU Zhi-peng¹, BAI Xiao-chun¹, LU Di, KE Zhi-yong¹, LUO Shen-qiu^{1*}

¹Department of Cell Biology, First Military Medical University, Guangzhou 510515, China; ²Department of General Surgery, Fuzhou General Hospital, Fuzhou, 350025 China

Abstract: Objective To determine whether the epidermal growth factor receptor (EGFR) expression contributes to tumor growth of poorly differentiated human nasopharyngeal carcinoma CNE-2 cell lines. Methods An expression vector containing a N-terminal fragment (1.35 kb) of human EGFR in the antisense orientation was transfected into CNE-2 cell lines via lipofectamine. The established clones resistant to G418 were isolated and characterized, and the tumor-inhibiting effect of antisense EGFR expression was evaluated in terms of tumor growth and metastasis at different times after subcutaneous inoculation into nude mice. Results Down-regulated EGFR expression in the cells with antisense vector transfection was demonstrated by ligand-binding assay. The growth rate and the ability to grow in soft agarose of these antisense transfectants were also reduced. After inoculation into nude mice, EGFR antisense transfectants showed a longer latency period, slower tumor growth and lower metastatic rates to the lymph nodes and lung in comparison with the parental cells. Conclusions These results suggest that these EGFR antisense cDNA-transfected CNE-2 cells are of value to further delineate the role of EGFR in the development and progression of nasopharyngeal carcinoma.

Key words: epidermal growth factor receptor; human nasopharyngeal carcinoma cells; antisense RNA; gene transfer

Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein with relative molecular weight of 17 000, consisting of extracellular ligand binding domain, transmembrane domain and intracellular tyrosine-kinase domain. A large number of ligands for EGFR have been characterized, including epidermal growth factor (EGF), transforming growth factor β (TGF- β), and amphiregulin. Binding of these ligands to extracellular domain of EGFR initiates a variety of biological responses, resulting in the activation of mitogenic signal transduction pathway to maintain balanced proliferation.

Several investigations have shown that amplification and/or overexpression of EGFR gene may be associated with the growth rate and malignancy of the tumors, which in turn has prognostic significance in patients with these tumors, suggesting that receptor-directed therapies may be useful as anticancer strategies. Although EGFR down-regulation by antisense EGFR cDNA transfection has been demonstrated in human breast cancer, rhabdomyosarcoma, colon cancer, non-small-cell lung cancer, and glioma cells, no such efforts have been attempted in human nasopharyngeal carcinoma cells.

Nasopharyngeal carcinoma (NPC) is one of the most frequent cancers in south China. Although Epstein-Barr virus has been shown to be the likely etiologic agent in nasopharyngeal carcinogenesis, the molecular pathogenesis of NPC remains to be elucidated. The first insight into the potential role of EGFR in NPC progression came from the observations of a monoclonal antibody against EGFR, which significantly inhibited the growth and tumorigenesis of human NPC cells both in vitro and in vivo. In this study, we transfected a plasmid containing a 1.35-kb gene fragment encoding the N-terminal fragment of human EGFR cDNA in the 3' to 5' orientation into NPC CNE-2 cell line with high EGFR expression and examined the effects of down-regulated EGFR expression on the growth behavior and tumorigenesis of the cells in nude mice.

MATERIAL AND METHODS

Cell lines and plasmids

Human nasopharyngeal carcinoma CNE-2 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (GIBCO/BRL). A 1.35-kb BamH1 fragment containing the extracellular region for EGFR derived from a full-length 4.0-kb human cDNA was cloned in the reverse 3' to 5' orientation into the pLXSN retrovirus vector as we described previously. Plasmid transfection and production of stable cell lines

DENG Fan: *To whom correspondence and reprint requests should be addressed, at Department of Cell Biology, First Military Medical University, Guangzhou 510515, China

The antisense EGFR expression vector pLXSN-AS5 and pLXSN control vector were respectively transfected into CNE-2 cells via lipofectamine (GIBCO/BRL) according to the manufacturer's instructions. Several G418-resistant clones were subsequently isolated and expanded. The stable integration and structural integrity of the plasmid DNA were examined by PCRs as we described previously^[1], and the selected clones of the cells with antisense EGFR expression vector transfection were designated as CNE-2/AS4 and CNE-2/AS8 respectively; pLXSN vector-transfected cells were designated as CNE-2/pLXSN.

¹²⁵I-EGF ligand binding assay

This assay was performed as described previously^[2].

The parental cells or transfected cells (CNE-2/pLXSN, CNE-2/AS4, and CNE-2/AS8) were plated at 2×10⁵/well into 24-well Nunc dishes and allowed to grow overnight. The confluent cultures were placed the following day on ice and washed once with wash buffer (containing 0.01% Mg²⁺ and 0.005% Ca²⁺ plus 1 mg/ml BSA of PBS) pre-cooled to 4 °C, prior to the addition of 1 ml unlabeled cold EGF (2.5–500 ng/ml) in wash buffer into the triplicate dishes and of ¹²⁵I-EGF (9×10⁴ cpm) into each well. The culture dishes were then rocked gently on ice for 4 h, the cells washed 5 times with the wash buffer, lysed with RRAlysis buffer (HEPES pH 7.3, 20 mmol/L, 10% glycerol, 1% Triton X-100) and counted in gamma counter. The results were under went computer program LIGAND analysis.

In vitro cell growth assay

The parental cells or transfected cells were seeded at 1×10⁴ cells/well and grown in triplicate 35-mm dishes for 8 d. The cells were harvested and counted by trypan blue exclusion on day 0, 2, 4, 6, and 8, respectively.

Anchorage-independent growth assay

Soft agarose assay was performed as described previously^[3]. In brief, 1×10³ cells/well were plated on 0.35% low-melting-point agarose in RPMI 1640 containing 15% fetal bovine serum. The colonies were scored under a magnifying glass after 10 days. Each soft agarose assay was done in triplicate.

Tumorigenicity and metastasis in nude mice

The parental cells or transfected cells were injected subcutaneously (1×10⁶ cells) into 6 female nude mice (4–5 weeks old). Mice were examined twice a week and the tumor size was measured using a caliper. Tumor

volumes (mm³) were calculated according to the formula: V = length × width²/2². After 77 days, the mice were killed and the tumor, lung and lymph node were removed respectively, fixed in neutral buffer formalin, embedded in paraffin, and sectioned for histological analysis.

RESULTS

Effect of EGFR antisense RNA expression on EGFR expression levels and binding affinity

After transfection of CNE-2 cells with the EGFR antisense RNA expression vector or the empty vector, G418-resistant clones were identified and isolated. Genomic DNA was extracted from the 4 selected CNE-2/AS clones, 1 CNE-2/pLXSN clone and the parental CNE-2 cells. A 433-bp fragment of integrated neogenese sequence was detected in the transfected CNE-2 cells, but not in the parental CNE-2 cells by PCR analysis (data not shown). Two representative CNE-2 clones CNE-2/AS4 and CNE-2/AS8 were reserved for later experimentation.

¹²⁵I-EGF binding and Scatchard analysis showed that the number of EGFR was reduced by 18% and 45% in the two selected clones (CNE-2/AS4, P<0.05; CNE-2/AS8, P<0.01) respectively, whereas the clones transfected with the empty vector (CNE-2/pLXSN) had similar EGFR levels to those of the parental cells (P>0.05). However, the binding affinity of EGFR to the ligand was not significantly affected by EGFR antisense RNA expression (Tab1).

Tab.1 Binding of ¹²⁵I-EGF to the parental and transfected CNE-2 clones (Mean±SD)

Cellline	Receptor No./cell	Binding affinity (Kd,nM)
CNE-2	67658±700	2.50±0.29
CNE-2/pLXSN	62273±900*	2.39±0.18*
CNE-2/AS4	55790±620**	2.13±0.50*
CNE-2/AS8	37512±30***	2.07±0.47*

*P>0.05, **P<0.05, ***P<0.01. The binding sites and binding affinity (ligand dissociation constant, Kd) were determined by Scatchard analyses. Student's t test was used for comparison between transfected clones and the parental cells.

Effect of EGFR antisense RNA on cell proliferation

In order to examine whether anti-sense EGFR RNAs suppresses the growth of the tumor cells in vitro, we plated 1×10⁴ CNE-2 cells in 35-mm plastic dishes containing RPMI 1640 supplemented with 10% FBS.

The number of viable cells in each dish was counted every other day. As shown in Fig.1, the proliferation rate significantly decreased in the transfected clones of CNE-2 cells expressing EGFR antisense RNA, as compared with that of the parental cells or CNE-2 cells transfected with the empty vector. A reduction by 33% and 55% in the cell number occurred 8 d after the plating of the CNE-2/AS4 and CNE-2/AS8 cells respectively (Fig.1). These results suggested that the extent of growth inhibition in EGFR antisense RNA-transfected clones as compared with the parental cells was in proportion to the degree of EGFR expression that was blocked.




Fig.1 In vitro growth inhibition of CNE-2 cells transfected with EGFR antisense cDNA vector compared with the parental cells or the cells transfected with the empty vector

Effect of EGFR antisense RNA on CNE-2 cell growth on soft agarose

The parental and transfected clones were examined for their colony-forming ability in soft agarose medium, which was an accepted criterion for transformation capacity assessment. As shown in Fig.2, the growth of CNE-2/AS4 or CNE-2/AS8 clones was inhibited by 40%-50% in comparison with the parental and CNE-2/pLXSN control clones. In addition, as expected, CNE-2/AS4 and CNE-2/AS8 cells formed smaller and less colonies on soft agarose than the parental and empty vector-transfected cells (data not shown). These results suggest that EGFR antisense RNA can suppress *in vitro* the tumorigenicity of CNE-2 cells.

Tumorigenicity and metastasis in nude mice

The tumorigenicity of the parental and transfected clones was examined in 6 female nude mice by subcutaneous injection. As shown in




Fig.2 Growth inhibition of CNE-2/AS4 and CNE-2/AS8 cells in soft agarose

Tab.2, all mice injected with CNE-2 cells and CNE-2/pLXSN cells rapidly developed aggressively growing tumor nodules at the site of inoculation after 3-5 d. However, EGFR antisense RNA-expressing clones showed a longer latency period (9-11 d) and slower tumor growth rate compared with those of the parental cells and CNE-2/pLXSN clones 1 month after the inoculation (Fig.3).

To investigate the effect of antisense EGFR RNA on the metastasis of the tumors *in vivo*, all mice were killed for histopathological examination on day 77 after injection, and the lungs and lymph nodes were removed. The sections obtained for histological analysis showed that CNE-2/AS4 cells had no lung metastasis with lower rate of lymph node metastasis than the parental and CNE-2/pLXSN cells, while CNE-2/AS8 cells had significantly different lymph node metastasis from that of the parental cells (Tab.2).

DISCUSSION

Overexpression of the epidermal growth factor receptor is frequent in human carcinoma, often accompanied by the expression of autocrine or paracrine transforming growth factor β which results in the activation of EGFR tyrosine kinase and phenotype transformation $\alpha\beta\gamma\delta$. CNE-2 cell line was established from biopsy of a poorly differentiated and moderately metastatic nasopharyngeal carcinoma $\alpha\beta\gamma\delta$. Previous investigations have demonstrated that EGFR overexpression associates with

Tab.2 Tumorigenicity and metastasis analysis of CNE-2 cell line transfected with antisense EGFR cDNA

Cellline	Nude mice	Tumorformation(days afterinoculation)	Lungmetastasis/total lungglobes	Lymphnodemetastasis/totalnumberoflymphnodes
CNE-2	6	3-5	4/25(16%)	28/39(71.8%)
CNE-2/pLXSN	6	4-5	3/25(12%)	22/44(50.0%)
CNE-2/AS4	6	9-11	0/30(0%)	19/43(44.2%)
CNE-2/AS8	6	10-11	2/30(6.6%)	24/42(57.1%)




Fig. 3 Inhibitory effect of EGFR antisense RNA expression on tumor growth in nude mice

the growth and tumorigenesis of CNE-2, which can be significantly inhibited by a monoclonal antibody against EGFR^[10], and we consequently chose this cell line to study the effect of EGFR antisense RNA expression.

Previous therapeutic strategies designed to interfere with EGFR signal transduction have used antisense oligonucleotides^[11], antisense RNA^[6,9,8] or the antibodies against EGFR^[7-19]. In this study, by an antisense RNA approach, we established CNE-2/AS cells (CNE-2/AS4, CNE-2/AS8) in which antisense RNA was generated by a sequence that was stably incorporated into the genome for consistent expression of the transcript. EGFR antisense RNA expression could significantly down-regulate the number of EGFR on the surface of the two CNE-2 cells transfected with EGFR antisense cDNA vector, as compared with the parental and CNE-2/pLXSN cells. However, the binding affinity of the EGFR for ligand is not significantly affected by antisense EGFR RNA. These results are essentially in accordance with the previous finding of Chakrabarty et al^[10], who demonstrated that a 31% reduction in the number of high-affinity cell surface EGFR and a 68% reduction in low-affinity cell-surface EGFR occurred in the human colon carcinoma Moser cells transfected with EGFR antisense cDNA vector, but the binding affinity of the EGFR for ligand remained unchanged.

The growth rate in vitro and the ability to grow in soft agarose of these two EGFR antisense vector-transfected cells were also significantly reduced. After injection into nude mice, EGFR antisense transfectants showed a longer latency period, slower tumor growth and lower lymph node and lung metastasis rates in comparison with the parental cells. In addition, tumor growth and tumorigenesis were proportional to the degree of EGFR expression inhibition in cells transfected with EGFR antisense cDNA vectors. However, com-

plete inhibition of the cell growth and tumorigenesis either in vitro or in vivo was not observed. A similar result was obtained by Moroni et al^[10], who demonstrated that the inhibition of the phenotype was directly proportional to the residual amount of EGF expressed in human epidermoid carcinoma KB cell with transfection of EGFR antisense RNA constructs.

Antisense RNA strategy have been successfully utilized to reduce the expression of a number of mammalian genes, including those for growth factors or related receptor genes^[10,2,21]. This is the first report to address the effect of EGFR antisense plasmid transfection in inhibiting the tumorigenicity and metastasis of human NPC cells, thereby providing a valuable target for therapeutic intervention of tumors with EGFR overexpression.

ACKNOWLEDGEMENTS

This work was supported by Natural Science Foundation of Guangdong Province. We also thank YANG Qing-yuan and LIU Shuang for their technical assistance.

REFERENCES

- ^[1] Khazaie K. EGFR in neoplasia and metastasis. *Cancer Metastasis Rev*, 1993, 12(3-4):255-74.
- ^[2] Mishima K, Asai A, Sugiyama A. Increased expression of schwannoma-derived growth factor (SDGF) mRNA in rat tumor cells: involvement of SDGF in the growth promotion of rat gliomas. *Int J Cancer*, 1996, 66(3):352-7.
- ^[3] Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. *Br Med Bull*, 1991, 47(1):87-98.
- ^[4] Fan WH, Lu YL, Deng F, et al. EGFR antisense RNA blocks expression of the epidermal growth factor receptor and partially reverses the malignant phenotype of human breast cancer MDA-MB-231 cells. *Cell Research*, 1998, 8(1):63-71.
- ^[5] Dixit M, Yang JL, Poirier MC, et al. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor receptor antisense RNA. *J Nat Cancer Inst*, 1997, 89(5):365-73.
- ^[6] DeGiovanni C, Landuzzi L, Frabetti F, et al. Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells. *Cancer Res*, 1996, 56(17):3898-901.
- ^[7] Chakrabarty S, Rajagopal S, Huang S. Expression of antisense epidermal growth factor receptor RNA downmodulates the malignant behavior of human colon cancer cells. *Clin Exp Metastasis*, 1995, 13(3):191-5.
- ^[8] Fang K, Chen MH. Transfection of anti-sense complementary DNA

- of human epidermal growth factor receptor attenuates the proliferation of human non-small lung cancer cells. *Int J Cancer*, 1999, 81(3):471-8.
- Tian XX, Pang JC, Zheng J, et al. Antisense epidermal growth factor receptor RNA transfection in human glioma cells down-regulates telomerase activity and telomere length. *Br J Cancer*, 2002, 86(8):1328-32.
- Guan EN, Zhou TC, Wang JH, et al. Effects of monoclonal antibody anti-EGF receptor on human nasopharyngeal carcinoma cell and other cells. *Sci China B (Chin)*, 1990, 33(11):1334-40.
- Tang WP, Huang PG, Shen SJ, et al. Establishment and characteristics of transplantation model of human epithelial cell strain of poorly differentiated nasopharyngeal carcinoma. *Cancer (Chin)*, 1989, 8(4):247-50.
- Lichtner RB, Kaufmann AM, Kittmann A, et al. Ligand-mediated activation of ectopic EGF receptor promotes matrix protein adhesion and lung colonization of rat mammary adenocarcinoma cells. *Oncogene*, 1995, 10(9):1823-32.
- Arteaga CL, Holt JT. Tissue-targeted antisense-fos retroviral vector inhibits established breast cancer xenografts in nude mice. *Cancer Res*, 1996, 56(5):1098-1103.
- Di Fiore PP, Pierce JH, Hazan R, et al. Over-expression of the human epidermal-growth-factor receptor confers a EGF-dependent transformed phase-type to NIH3T3 cells. *Cell*, 1987, 51(6):1063-70.
- Wang S, Lee RJ, Cauchon G, et al. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor Receptor into Cultured KB cells with liposomes conjugated to folate via polyethylene Glycol. *Proc Natl Acad Sci (Wash.)*, 1995, 92(8):3318-22.
- Pu P, Liu X, Liu A, et al. Inhibitory effect of antisense epidermal growth factor receptor RNA on the proliferation of rat C6 glioma cells in vitro and in vivo. *Neurosurg*, 2000, 92(1):132-9.
- Ma L, Gauville C, Berthois Y, et al. Calvo F. Role of epidermal growth factor receptor in tumor progression in transformed human mammary epithelial cells. *Int J Cancer*, 1998, 78(1):112-9.
- Divgi CR, Welt S, Kris M, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. *J Natl Cancer Inst*, 1991, 83(2):97-104.
- Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. *J Natl Cancer Inst*, 1993, 85(16):1327-33.
- Ueno H, Sasaki K, Miyagawa K, et al. Hirai H. Antisense repression of proto-oncogene c-Cbl enhances activation of the JAK-STAT pathway but not the Ras pathway in epidermal growth factor receptor signaling. *J Biol Chem*, 1997, 272(13):8739-43.
- He Y, Zeng Q, Drenning SD, et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. *J Natl Cancer Inst*, 1998, 90(14):1080-7.

EGFR反义 RNA 的转染对人类鼻咽癌 CNE-2 细胞 EGFR 的表达下调及恶性表型的抑制

邓凡¹袁瑜²曾方银¹郭志鹏¹袁白晓春¹吴地¹袁河志勇¹袁罗深秋¹渊第一军医大学细胞生物学教研室^{袁东}广州 510515¹福州总医院普外科^{袁福建}福州 350025^冤

摘要 目的 利用反义 RNA 抑制靶基因表达的策略下调 EGFR 的表达而探讨对人类低分化鼻咽癌 CNE-2 细胞的恶性表型的抑制性效应。方法 将人 EGFR 的 N- 端 1.35kb 片段反向构建入逆转录病毒表达载体 pLXSN 中并用脂质体介导转染人鼻咽癌 CNE-2 细胞^{袁418}筛选并分离阳性克隆袁将两个 EGFR 反义 cDNA 转染的克隆细胞命名为 CNE-2/AS4 和 CNE-2/AS8^{袁而}空载体转染的细胞命名为 CNE-2/pLXSN^{袁125I-EGF 配体结合分析}细胞膜上 EGFR 的表达^{袁台盼蓝染色法测定}细胞生长的改变^{袁并用软琼脂集落形成实验检测}细胞转化^{袁最后袁将筛选的各组阳性克隆细胞分别注射入裸鼠皮下袁不同时间观察肿瘤生长的抑制改变及肿瘤的转移状况^{袁结果}配体结合实验结果显示袁两个选择的克隆 CNE-2/AS4 和 CNE-2/AS8 细胞表面 EGFR 的数量分别较未转染细胞 CNE-2 下降 18% 袁 5% 袁表明 EGFR 反义 RNA 的表达下调了细胞膜上 EGFR 的表达^{袁同时袁GFR 反义 RNA 表达的 CNE-2 细胞生长速率和软琼脂生长能力也}较对照组细胞明显降低^{袁注射入裸鼠皮下后袁GFR 反义 RNA 表达的阳性克隆细胞表现出肿瘤生长减慢袁淋巴结和肺转移能力也明显降低^{袁结论} 这些实验结果提示 EGFR 反义 cDNA 转染的 CNE-2 细胞能下调 EGFR 的过量表达并部分抑制鼻咽癌的恶性表型袁这为进一步阐明 EGFR 在鼻咽癌的发生演化中的功能作用提供了有用的工具^袁}}

关键词 表皮生长因子受体^袁鼻咽癌细胞^袁反义 RNA^袁基因转移